148 related articles for article (PubMed ID: 34612846)
1. Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial.
Tom J; Bao M; Tsai L; Qamra A; Summers D; Carrasco-Triguero M; McBride J; Rosenberger CM; Lin CJF; Stubbings W; Blyth KG; Carratalà J; François B; Benfield T; Haslem D; Bonfanti P; van der Leest CH; Rohatgi N; Wiese L; Luyt CE; Kheradmand F; Rosas IO; Cai F
Crit Care Med; 2022 Mar; 50(3):398-409. PubMed ID: 34612846
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
3. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.
Rosas IO; Bräu N; Waters M; Go RC; Hunter BD; Bhagani S; Skiest D; Aziz MS; Cooper N; Douglas IS; Savic S; Youngstein T; Del Sorbo L; Cubillo Gracian A; De La Zerda DJ; Ustianowski A; Bao M; Dimonaco S; Graham E; Matharu B; Spotswood H; Tsai L; Malhotra A
N Engl J Med; 2021 Apr; 384(16):1503-1516. PubMed ID: 33631066
[TBL] [Abstract][Full Text] [Related]
4. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
[TBL] [Abstract][Full Text] [Related]
5. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-6 blocking agents for treating COVID-19: a living systematic review.
Ghosn L; Chaimani A; Evrenoglou T; Davidson M; Graña C; Schmucker C; Bollig C; Henschke N; Sguassero Y; Nejstgaard CH; Menon S; Nguyen TV; Ferrand G; Kapp P; Riveros C; Ávila C; Devane D; Meerpohl JJ; Rada G; Hróbjartsson A; Grasselli G; Tovey D; Ravaud P; Boutron I
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013881. PubMed ID: 33734435
[TBL] [Abstract][Full Text] [Related]
7. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
8. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
Cotter A; Wallace D; McCarthy C; Feeney E; O'Neill L; Stack J; McCarthy G; Hussain R; Alvarez Barco E; Doran P; Mallon P
Trials; 2020 Sep; 21(1):758. PubMed ID: 32883328
[TBL] [Abstract][Full Text] [Related]
9. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
[TBL] [Abstract][Full Text] [Related]
10. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
11. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.
Veiga VC; Prats JAGG; Farias DLC; Rosa RG; Dourado LK; Zampieri FG; Machado FR; Lopes RD; Berwanger O; Azevedo LCP; Avezum Á; Lisboa TC; Rojas SSO; Coelho JC; Leite RT; Carvalho JC; Andrade LEC; Sandes AF; Pintão MCT; Castro CG; Santos SV; de Almeida TML; Costa AN; Gebara OCE; de Freitas FGR; Pacheco ES; Machado DJB; Martin J; Conceição FG; Siqueira SRR; Damiani LP; Ishihara LM; Schneider D; de Souza D; Cavalcanti AB; Scheinberg P;
BMJ; 2021 Jan; 372():n84. PubMed ID: 33472855
[TBL] [Abstract][Full Text] [Related]
12. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.
Salvarani C; Dolci G; Massari M; Merlo DF; Cavuto S; Savoldi L; Bruzzi P; Boni F; Braglia L; Turrà C; Ballerini PF; Sciascia R; Zammarchi L; Para O; Scotton PG; Inojosa WO; Ravagnani V; Salerno ND; Sainaghi PP; Brignone A; Codeluppi M; Teopompi E; Milesi M; Bertomoro P; Claudio N; Salio M; Falcone M; Cenderello G; Donghi L; Del Bono V; Colombelli PL; Angheben A; Passaro A; Secondo G; Pascale R; Piazza I; Facciolongo N; Costantini M;
JAMA Intern Med; 2021 Jan; 181(1):24-31. PubMed ID: 33080005
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
[TBL] [Abstract][Full Text] [Related]
14. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA).
Rosas IO; Bräu N; Waters M; Go RC; Malhotra A; Hunter BD; Bhagani S; Skiest D; Savic S; Douglas IS; Garcia-Diaz J; Aziz MS; Cooper N; Youngstein T; Sorbo LD; Zerda DJ; Ustianowski A; Gracian AC; Blyth KG; Carratalà J; François B; Benfield T; Haslem D; Bonfanti P; van der Leest CH; Rohatgi N; Wiese L; Luyt CE; Bauer RN; Cai F; Lee IT; Matharu B; Metcalf L; Wildum S; Graham E; Tsai L; Bao M
EClinicalMedicine; 2022 May; 47():101409. PubMed ID: 35475258
[TBL] [Abstract][Full Text] [Related]
16. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.
Salama C; Han J; Yau L; Reiss WG; Kramer B; Neidhart JD; Criner GJ; Kaplan-Lewis E; Baden R; Pandit L; Cameron ML; Garcia-Diaz J; Chávez V; Mekebeb-Reuter M; Lima de Menezes F; Shah R; González-Lara MF; Assman B; Freedman J; Mohan SV
N Engl J Med; 2021 Jan; 384(1):20-30. PubMed ID: 33332779
[TBL] [Abstract][Full Text] [Related]
17. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
[TBL] [Abstract][Full Text] [Related]
18. Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial.
Caricchio R; Abbate A; Gordeev I; Meng J; Hsue PY; Neogi T; Arduino R; Fomina D; Bogdanov R; Stepanenko T; Ruiz-Seco P; Gónzalez-García A; Chen Y; Li Y; Whelan S; Noviello S;
JAMA; 2021 Jul; 326(3):230-239. PubMed ID: 34283183
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.
Stone JH; Frigault MJ; Serling-Boyd NJ; Fernandes AD; Harvey L; Foulkes AS; Horick NK; Healy BC; Shah R; Bensaci AM; Woolley AE; Nikiforow S; Lin N; Sagar M; Schrager H; Huckins DS; Axelrod M; Pincus MD; Fleisher J; Sacks CA; Dougan M; North CM; Halvorsen YD; Thurber TK; Dagher Z; Scherer A; Wallwork RS; Kim AY; Schoenfeld S; Sen P; Neilan TG; Perugino CA; Unizony SH; Collier DS; Matza MA; Yinh JM; Bowman KA; Meyerowitz E; Zafar A; Drobni ZD; Bolster MB; Kohler M; D'Silva KM; Dau J; Lockwood MM; Cubbison C; Weber BN; Mansour MK;
N Engl J Med; 2020 Dec; 383(24):2333-2344. PubMed ID: 33085857
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of severe acute respiratory syndrome coronavirus-2 viral load and antibodies in patients hospitalized with COVID-19.
Bauer RN; Teterina A; Shivram H; McBride J; Rosenberger CM; Cai F; Bao M; Tsai L; Gordon O; Lee IT; Wallin JJ; Porter D; Juneja K; Camus G; Rosas IO; Wildum S
Clin Transl Sci; 2023 Jun; 16(6):1049-1062. PubMed ID: 36929625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
